Dr. Michael T. Schweizer, M.D.
Medical Oncology (Medical Oncology Physician)
825 Eastlake Ave E
Seattle, WA 98109
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 186
Licensed in Washington since 2014, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Temple University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WA license MD60473280 (first issued 2014; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
- Tacoma General Allenmore Hospital Tacoma, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 186
- Services billed
- 461
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 348 | 148 |
| New patient office or other outpatient visit, 60-74 minutes | 44 | 44 |
| Established patient office or other outpatient visit, 30-39 minutes | 30 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Seattle, WA | 109 |
| Abiraterone Acetate | 89 |
| Nubeqa (darolutamide) | 19 |
| Dexamethasone Other prescribers in Seattle, WA | 19 |
| Ondansetron Hcl Other prescribers in Seattle, WA | 19 |
| Prochlorperazine Maleate Other prescribers in Seattle, WA | 15 |
| Xtandi (enzalutamide) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $5,850 in total to this clinician.
| Daiichi Sankyo Inc. | $4,050 |
|---|---|
| Pfizer Inc. | $1,800 |
| Consulting Fee | $5,850 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Feb 13, 2025 | Consulting Fee | $2,363 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $1,800 |
| Daiichi Sankyo Inc. Oct 15, 2025 | Consulting Fee | $1,688 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 7 companies. The companies reported $2,855,038 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Janssen Research & Development, LLC - A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathwa…
Janssen Research & Development, LLC - A phase i dose escalation and expanded cohort study of PF06821497 in the treatment of adult patients with relapsedrefractory small cell lung cancer sclc castration resistant prostate cancer crpc and follicular lymphom…
Pfizer Inc. - A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
Pfizer Inc. - A phase 3 randomized double blind placebo controlled study of PF06821497 mevrometostat with enzalutamide in metastatic castration resistant prostate cancer MEVPRO2
Pfizer Inc. - PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Re…
Novartis Pharmaceuticals Corporation - A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer
Novartis Pharmaceuticals Corporation - A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer
Celgene Corporation - A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer
Janssen Research & Development, LLC - A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.